New diet drugs are making it easier to lose weight. So does that mean we can stop exercising? Health experts say no. There is ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their impact on the brain, pointing to benefits from addiction to schizophrenia.

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

While weight-loss drugs were linked to lower risk of some conditions, they were also associated with some adverse health ...

GLP-1 drugs like Ozempic have swept the world as effective therapies for far more than their original target of diabetes.